Granted Patent
B2
US 12,371,472 · App. 18/498,430 · Granted Jul 29, 2025
Multimeric IL-15 soluble fusion molecules and methods of making and using same
Inventors:
Hing C. Wong (Weston, FL); Peter Rhode (Miami, FL); Bai Liu (Cooper City, FL); Xiaoyun Zhu (Weston, FL); Kai-Ping Han (Weston, FL)
Assignee:
Altor Bioscience, LLC
C07K14/7155A61K38/1793A61K38/2086A61K39/3955A61K45/06C07K14/5443C07K16/18C07K16/2887C12N15/09C12N15/62C12P21/00A61K38/00C07K2317/622C07K2317/732C07K2319/00C07K2319/21C07K2319/22C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
Claims (11)
1. A method of stimulating CD8+ memory T cells and effector NK cells in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an Interleukin-15N72D: Interleukin-15 receptor alpha Sushi/Fc (IL-15N72D: IL-15RαSu/Fc; ALT-803) complex, wherein the complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules.
2. The method of claim 1 , wherein the effective amount is between 1 μg/kg and 20 μg/kg.
3. The method of claim 2 , wherein the effective amount is 15 μg/kg.
4. The method of claim 1 , wherein the effective amount is between 20 μg/kg and 100 μg/kg.
5. The method of claim 4 , wherein the effective amount is 30 μg/kg.
6. The method of claim 1 , wherein the pharmaceutical composition comprising the IL-15N72D: IL-15RαSu/Fc complex is administered once per week.
7. The method of claim 1 , wherein the pharmaceutical composition is administered systemically, intravenously, subcutaneously or by instillation into the bladder.
8. The method of claim 1 , wherein the subject has increased levels of serum Interferon gamma (IFNγ).
9. The method of claim 1 , wherein the subject has a neoplasia.
10. The method of claim 9 , wherein the neoplasia is beta cell lymphoma, urothelial/bladder carcinoma, melanoma, breast cancer, multiple myeloma, or pancreatic cancer.
11. The method of claim 1 , wherein the subject has a viral infection.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 8, 2023
From: WONG, HING C.; RHODE, PETER; LIU, BAI; ZHU, XIAOYUN; HAN, KAI-PING
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 065494/0035 →
MERGER
Recorded Nov 8, 2023
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE LLC
Reel/Frame 065494/0094 →
Continuity (11)
Provisional Application
61527911
· Aug 26, 2011
Provisional Application
61384817
· Sep 21, 2010
References Cited (327)
US 5116964A
· Capon et al.
· 1992
[cited by applicant]
US 5541087A
· Lo et al.
· 1996
[cited by applicant]
US 5620939A
· Halasa et al.
· 1997
[cited by applicant]
US 6344192B1
· Grooten et al.
· 2002
[cited by applicant]
US 8124084B2
· Lefrancois et al.
· 2012
[cited by applicant]
US 8163879B2
· Wong et al.
· 2012
[cited by applicant]
US 8492118B2
· Wong et al.
· 2013
[cited by applicant]
US 8507222B2
· Wong et al.
· 2013
[cited by applicant]
US 8940288B2
· Lefrancois et al.
· 2015
[cited by applicant]
US 8940289B2
· Wong et al.
· 2015
[cited by applicant]
US 9255141B2
· Wong et al.
· 2016
[cited by applicant]
US 9328159B2
· Wong et al.
· 2016
[cited by applicant]
US 9365630B2
· Lefrancois et al.
· 2016
[cited by applicant]
US 9428573B2
· Wong et al.
· 2016
[cited by applicant]
US 9464127B2
· Wong et al.
· 2016
[cited by applicant]
US 9593152B2
· Wong et al.
· 2017
[cited by applicant]
US 9629877B2
· Cooper et al.
· 2017
[cited by applicant]
US 9925247B2
· Klu et al.
· 2018
[cited by applicant]
US 20030180888A1
· Fraser
· 2003
[cited by applicant]
US 20040156826A1
· Dangond et al.
· 2004
[cited by applicant]
US 20040242025A1
· Angerpointner et al.
· 2004
[cited by applicant]
US 20040253587A1
· Grabstein et al.
· 2004
[cited by applicant]
US 20060263857A1
· LeFrancois et al.
· 2006
[cited by applicant]
US 20090010966A1
· Davis et al.
· 2009
[cited by applicant]
US 20090117618A1
· Hermann et al.
· 2009
[cited by applicant]
US 20090238791A1
· Jacques et al.
· 2009
[cited by applicant]
US 20130121960A1
· Sadelain et al.
· 2013
[cited by applicant]
US 20140099254A1
· Chang et al.
· 2014
[cited by applicant]
US 20150023938A1
· Yee
· 2015
[cited by applicant]
US 20170088597A1
· Wong et al.
· 2017
[cited by applicant]
AU 2008253720
· 2014
[cited by applicant]
AU 2013273643
· 2016
[cited by applicant]
AU 2011305476
· 2016
[cited by applicant]
AU 2016326575
· 2018
[cited by applicant]
AU 2017201056
· 2018
[cited by applicant]
AU 2015284248
· 2020
[cited by applicant]
CA 2811734
· 2012
[cited by applicant]
CA 2953816
· 2016
[cited by applicant]
CA 2999294
· 2017
[cited by applicant]
CA 2690825
· 2019
[cited by applicant]
CN 1441675
· 2003
[cited by applicant]
CN 1478098
· 2004
[cited by applicant]
CN 1493687
· 2004
[cited by applicant]
CN 1760209
· 2006
[cited by applicant]
CN 1780856
· 2006
[cited by applicant]
CN 1942481
· 2007
[cited by applicant]
CN 101484472
· 2009
[cited by applicant]
CN 101743249A
· 2010
[cited by applicant]
CN 104672325
· 2015
[cited by applicant]
CN 105017429
· 2015
[cited by applicant]
CN 106659775
· 2017
[cited by applicant]
CN 101743249B
· 2017
[cited by applicant]
CN 103370339
· 2017
[cited by applicant]
CN 104109200
· 2018
[cited by applicant]
CN 107880136
· 2018
[cited by applicant]
CN 108463239
· 2018
[cited by applicant]
CN 108948177
· 2018
[cited by applicant]
EP 0971728
· 2000
[cited by applicant]
EP 1777294
· 2007
[cited by applicant]
EP 1934353
· 2008
[cited by applicant]
EP 2388266A2
· 2011
[cited by applicant]
EP 2537933
· 2012
[cited by applicant]
EP 2388266B1
· 2014
[cited by applicant]
EP 2160401
· 2014
[cited by applicant]
EP 2619229
· 2016
[cited by applicant]
EP 3160498
· 2017
[cited by applicant]
EP 2769984
· 2017
[cited by applicant]
EP 2918607
· 2017
[cited by applicant]
EP 3305805
· 2018
[cited by applicant]
EP 3327040
· 2018
[cited by applicant]
EP 3352779
· 2018
[cited by applicant]
EP 3673915
· 2020
[cited by applicant]
EP 3912637
· 2021
[cited by applicant]
JP H0687898
· 1994
[cited by applicant]
JP H09512165
· 1997
[cited by applicant]
JP H11500908
· 1999
[cited by applicant]
JP 2001502521
· 2001
[cited by applicant]
JP 2008545397
· 2008
[cited by applicant]
JP 2009512433
· 2009
[cited by applicant]
JP 2010527919
· 2010
[cited by applicant]
JP 6251570
· 2011
[cited by applicant]
JP 2013541335
· 2013
[cited by applicant]
JP 5501222
· 2014
[cited by applicant]
JP 2014524737
· 2014
[cited by applicant]
JP 5841623
· 2015
[cited by applicant]
JP 6152156
· 2017
[cited by applicant]
JP 2017521410
· 2017
[cited by applicant]
JP 2018046831
· 2018
[cited by applicant]
JP 6408039
· 2018
[cited by applicant]
JP 2018174697
· 2018
[cited by applicant]
JP 2018532729
· 2018
[cited by applicant]
JP 2019033754
· 2019
[cited by applicant]
KR 1020070002052
· 2007
[cited by applicant]
KR 1020140020228
· 2014
[cited by applicant]
KR 1020170047221
· 2017
[cited by applicant]
KR 20180125435
· 2018
[cited by applicant]
KR 102070098
· 2020
[cited by applicant]
MX 2017000116
· 2017
[cited by applicant]
WO WO9404689
· 1994
[cited by applicant]
WO WO9429350
· 1994
[cited by applicant]
WO WO9527722
· 1995
[cited by applicant]
WO WO9626274
· 1996
[cited by applicant]
WO WO9632478
· 1996
[cited by applicant]
WO WO9734631
· 1997
[cited by applicant]
WO WO9741232
· 1997
[cited by applicant]
WO WO9836768
· 1998
[cited by applicant]
WO WO01056387
· 2001
[cited by applicant]
WO WO0187330
· 2001
[cited by applicant]
WO WO2005046449
· 2005
[cited by applicant]
WO WO2005085282
· 2005
[cited by applicant]
WO WO2006063974
· 2006
[cited by applicant]
WO WO2007001677
· 2007
[cited by applicant]
WO WO2007046006
· 2007
[cited by applicant]
WO WO2008143794
· 2008
[cited by applicant]
WO WO2009002562
· 2008
[cited by applicant]
WO WO2009117117
· 2009
[cited by applicant]
WO WO2012040323
· 2012
[cited by applicant]
WO WO2012175222
· 2012
[cited by applicant]
WO WO2013076183
· 2013
[cited by applicant]
WO WO2014028776
· 2014
[cited by applicant]
WO WO2014066527
· 2014
[cited by applicant]
WO WO2016004060
· 2016
[cited by applicant]
WO WO2017053649
· 2017
[cited by applicant]
WO WO2017205726
· 2017
[cited by applicant]
Dowlatshahi et al., “Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses,” Journal of Investigative Dermatology, 2013, vol. 133, pp. 1879-…
[cited by applicant]
Mugiya et al., Long-term Outcome of a Low-dose Intravesical Bacillus Calmette-Guerin Therapy for Carcinoma In Situ of the Bladder: Results After Six Successive Instillations of 40 mg BCG, Jpn. J. Clin. Oncol. 2005, vol.…
[cited by applicant]
Merck Company Statement, “Merck Announces Generic Name for MK-3475, Merck's Investigational anti-PD-1 Antibody: Pembrolizumab,” retrieved Feb. 28, 2024 online from www.merck.com/news/merck-announces-generic-name-for-mk-…
[cited by applicant]
Mishra et al., Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer, Clinical Cancer Research, Apr. 15, 2014, vol. 20(8), pp. 2044-2050.
[cited by applicant]
Reck et al., “Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer,” The New England Journal of Medicine, Nov. 10, 2016, vol. 375(19), pp. 1823-1833.
[cited by applicant]
Shitara et al., “Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer; The KEYNOTE-062 Phase 3 Randomized Clinical Trial,” J…
[cited by applicant]
U.S. Appl. No. 13/238,925, filed Sep. 21, 2011 now U.S. Pat. No. 8,507,222.
[cited by applicant]
U.S. Appl. No. 13/769,179, filed Feb. 15, 2013 now U.S. Pat. No. 9,255,141.
[cited by applicant]
U.S. Appl. No. 13/854,903, filed Apr. 1, 2013 now U.S. Pat. No. 9,328,159.
[cited by applicant]
U.S. Appl. No. 15/083,998, filed Mar. 29, 2016 now U.S. Pat. No. 10,150,805.
[cited by applicant]
U.S. Appl. No. 15/951,042, filed Apr. 11, 2018 now U.S. Pat. No. 10,899,821.
[cited by applicant]
U.S. Appl. No. 16/442,265, filed Jun. 14, 2019 now U.S. Pat. No. 11,053,299.
[cited by applicant]
U.S. Appl. No. 16/749,967, filed Jan. 22, 2020 now U.S. Pat. No. 11,104,716.
[cited by applicant]
U.S. Appl. No. 17/385,714, filed Jul. 26, 2021 now U.S. Pat. No. 11,845,783.
[cited by applicant]
U.S. Appl. No. 16/749,955, filed Jan. 22, 2020 now U.S. Pat. No. 11,046,747.
[cited by applicant]
U.S. Appl. No. 13/946,313, filed Jul. 19, 2013 now U.S. Pat. No. 9,428,573.
[cited by applicant]
U.S. Appl. No. 15/213,991, filed Jul. 19, 2016 now U.S. Pat. No. 10,358,478.
[cited by applicant]
Correia et al., “IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion,” Immunobiology, 2011, vol. 216, pp. 604-612.
[cited by applicant]
Extended European Search Report for European Patent Application No. 24169784.6, dated Aug. 12, 2024 7 pages.
[cited by applicant]
Gene Characterization Kits (1988), Strategene Catalog, 2 pages.
[cited by applicant]
Alpdogan et al. (Jan. 2005) “IL-7 and IL-15: Therapeutic Cytokines for Immunodeficiency”, Trends in Immunology, 25-26(1):56-64.
[cited by applicant]
Anderson et al. (1995) “Functional Characterization of the Human Interleukin-15 Receptor a Chain and Close Linkage of IL 15RA and IL2RA Genes”, The Journal of Biological Chemistry, 270(50):29862-29869.
[cited by applicant]
Anonymous (May 15, 2014) “A Study of Intravesical BCG in Combination With ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer”, ClinicalTrials.gov, NTC02138734, 9 Pages.
[cited by applicant]
Bailey et al. (2013) “New Interleukin-15 Superagonist (IL-15 SA) Significantly Enhances Graft-Versus-Tumor Activity After Allogeneic Hematopoietic Stem Cell Transplantation”, Blood, 122(21):05 pages.
[cited by applicant]
Bailey et al. (Jul. 4, 2017) “New Interleukin-15 Superagonist (IL-15SA) Significantly Enhances Graft-versus-tumor Activity”, Oncotarget, 8(27):44366-44378.
[cited by applicant]
Bazan et al. (Dec. 2012) “Phage display-A Powerful Technique for Immunotherapy”, Human Vaccines & Immunotherapeutics, 8(12):1817-1828.
[cited by applicant]
Beers et al. (1999) “The Merck Manual of Diagnosis and Therapy”, 17th Edition, 986-995.
[cited by applicant]
Belmont et al. (Oct. 2006) “Potent Antitumor Activity of a Tumor-specific Soluble TCR/IL-2 Fusion Protein”, Journal of Clinical Immunology, 121(1):29-39.
[cited by applicant]
Benton et al. (Apr. 8, 1977) “Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ”, Science, 196(4286):180-182.
[cited by applicant]
Bergamaschi et al. (Feb. 15, 2008) “Intracellular Interaction of Interleukin-15 with its Receptor Alpha during Production Leads to Mutual Stabilization and Increased Bioactivity”, Journal of Biological Chemistry, 28(7):…
[cited by applicant]
Bernard et al. (Jun. 4, 2004) “Identification of an Interleukin-15α Receptor-binding Site on Human Interleukin-15”, Journal of Biological Chemistry, 279(23):24313-24322.
[cited by applicant]
Bessard et al. (Sep. 2009) “High Antitumor Activity of RLI, An Interleukin-15 (IL-15)-IL-15 Receptor a Fusion Protein, in Metastatic Melanoma and Colorectal Cancer”, Molecular Cancer Therapeutics, 8(9):2736-2745.
[cited by applicant]
Bevan (Aug. 1997) “In Thymic Selection, Peptide Diversity Gives and Takes Away”, Immunity, 7(2): 175-178.
[cited by applicant]
Bjorkman (Apr. 18, 1997) “MHC Restriction in Three Dimensions: A View of T Cell Receptor/Ligand Interactions”, Cell, 89(2):167-170.
[cited by applicant]
Bork, Peer, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, vol. 10 (2000):398-400.
[cited by applicant]
Borras et al. (Mar. 19, 2010) “Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal Antibodies”, The Journal of Biological Chemistry, 285(12):9054-9066.
[cited by applicant]
Bouchaud et al., “The Exon-3-Encoded Domain of IL-15Rα Contributes to IL-15 High-Affinity Binding and Is Crucial for the IL-15 Antagonistic Effect of Soluble IL-15Rα”, Journal of Molecular Biology, Sep. 26, 2008, vol. 3…
[cited by applicant]
Bruhns (Apr. 16, 2009) “Specificity and Affinity of Human Fcγ Receptors and their Polymorphic Variants for human IgG Subclasses”, Blood, 113(16):3716-3725.
[cited by applicant]
Burkett et al., “IL-15Rα expression on CD8+ T cells is dispensable for T cell memory,” Proceedings of the National Academy of Sciences (PNAS), Apr. 15, 2003, vol. 100(8), pp. 4724-4729.
[cited by applicant]
Byers, “What Can Randomized Controlled Trials Tell Us About Nutrition and Cancer Prevention?,” CA Journal, vol. 49(6), Nov./Dec. 1999, 9 pages.
[cited by applicant]
Cany et al. (Jan. 11, 2018) “Decitabine Enhances Targeting of AML Cells by CD34+ Progenitor-Derived NK Cells in NOD/SCID/IL2Rgnull Mice”, Blood, 131(2):202-214.
[cited by applicant]
Capon et al. (Feb. 9, 1989) “Designing CD4 Immunoadhesins for AIDS Therapy”, Nature, 337(6207):525-531.
[cited by applicant]
Chae et al. (1996) “Mutant IL-15 Protein Exerting Antagonistic Effects on IL-15 Triggered Cell Proliferation”, Journal of the American Society of Nephrology, 7(9):1654.
[cited by applicant]
Chamow et al. (Feb. 1996) “Immunoadhesins: Principles and Applications”, Trends Biotechnology, 14:52-60.
[cited by applicant]
Chu et al. (Mar. 2016) “Therapeutic Effects of AL T-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer Cells Against Burkitt Lymphoma (BL)”, Biology of B…
[cited by applicant]
Cragg et al. (Apr. 1, 2004) “Antibody Specificity Controls in Vivo Effector Mechanisms of Anti-Cd20 Reagents”, Blood, 103(7) :2738-274 3.
[cited by applicant]
Database UniProt Sequence, retrieved from EBI, Database Accession No. 097687, XP002659759 (1999), 1 page, 1999.
[cited by applicant]
Database UniProt Sequence, retrieved from EBI, Database Accession No. Q6B416, XP002659761, 1 page, 2004.
[cited by applicant]
Database UniProt Sequence, retrieved from EBI, Database Accession No. Q8SPYO, XP002659760, 1 page, 2002.
[cited by applicant]
Davis (1985) “Molecular Genetics of the T Cell-receptor Beta Chain”, Annual Review of Immunology, 3:537-560.
[cited by applicant]
Davis (1998) “Ligand Recognition by aß T Cell Receptors”, Annual Reviews Immunology, 16:523-544.
[cited by applicant]
Davis et al. (Aug. 4, 1988) “T-cell Antigen Receptor Genes and T-cell Recognition”, Nature, 334(6181):395-402.
[cited by applicant]
Disis et al., “Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity,” Journal of Clinical Oncology, 2016 ASCO …
[cited by applicant]
Doerks, Tobias et al., “Protein annotation: detective work for function prediction,” TIG, vol. 14, Issue 6 (1998):248-250.
[cited by applicant]
Dubois et al. (2008) “Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action”, Journal of Immunology, 180(4):2099-2106.
[cited by applicant]
Dubois et al. (Sep. 17, 1999) “Natural Splicing of Exon 2 of Human Interleukin-15 Receptor a-Chain mRNA Results in a Shortened Form with a Distinct Pattern of Expression”, The Journal of Biological Chemistry, 274(38):26…
[cited by applicant]
Dudley et al. (Sep. 2003) “Adoptive-Cell-Transfer Therapy for the Treatment of Patients with Cancer”, Nature Review Cancer, 3:665-695.
[cited by applicant]
Epardaud et al. (Apr. 15, 2008) “Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells”, Cancer Research, 68(8):2972-2983.
[cited by applicant]
Fabbi et al. (2016) “Dual Roles of IL-15 in Cancer Biology”, Journal of Cytokine Biology, 1(2):103, 7 pages.
[cited by applicant]
Felices et al. (Dec. 2016) “CD16-IL 15-CD33 Trispecific Killer Engager (TrikE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics”, …
[cited by applicant]
Ferrari-Lacraz et al. (Sep. 15, 2001) “An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection”, Journal of Immunology, 167(6): 3478-3485.
[cited by applicant]
Fleer (Oct. 1992) “Engineering Yeast for High Level Expression”, Current Opinion in Biotechnology, 3(5):486-496.
[cited by applicant]
Galfre, et al., (1981) “Preparation of Monoclonal Antibodies: Strategies and Procedures”, Methods in Enzymology, 73(Pt B):3-46, publication nummary, 2 pages.
[cited by applicant]
Gillies et al. (May 15, 2005) “An Anti-CD20-IL-2 Immunocytokine is Highly Efficacious in A SCIO Mouse Model of Established Human B Lymphoma”, Blood, 105(10):3972-3978.
[cited by applicant]
Giron-Michel et al., “Membrane-bound and soluble IL-15IL-15Ra complexes display differential signaling and functions on human hematopoietic progenitors,” Blood, Oct. 1, 2005; pre-published online in Jun. 2005, vol. 106(…
[cited by applicant]
Gomes et al. (May 5, 2013) “IL-15 Analogue (ALT-803) Targeting T Regulatory Cells Causes Tomor Burden Reduction in an Orthotopic Non-Muscle Invasive Bladder Cancer Model,” The Journal of Urology, 189(4S):e238-e239.
[cited by applicant]
Gomes-Giacoia et al. (Jun. 4, 2014) “Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion”, PLoS One, e96705,…
[cited by applicant]
Graham et al. (Jul. 1977) “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”, Journal of General Virology, 36(1):59-72.
[cited by applicant]
Granziero et al., “Adoptive immunotherapy prevents prostate cancer in a transgenic animal model,” European Journal of Immunology, 1999, vol. 29, pp. 1127-1138.
[cited by applicant]
Grunstein et al. (Oct. 1975) “Colony Hybridization: A Method for the Isolation of Cloned DNAs That Contain a Specific Gene”, Proceedings of the National Academy of Sciences of the United States of America, 72(10):3961-3…
[cited by applicant]
Guglielmi et al. (Jul. 15, 2002) “Donor lymphocyte infusion for relapsed chronic myelogenous leuken1 ia: prognostic relevance of the initial cell dose”, Blood, 100(2):295-307.
[cited by applicant]
Guo et al., “Immunobiology of the IL-15-IL-15Rα Complex as an Antitumor and Antiviral Agent,” Cytokine Growth Factor Rev., Dec. 2017, vol. 38, pp. 10-21, 31 pages.
[cited by applicant]
Han et al., “IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization”, Cytokine, Sep. 28, 2011, vol. 56(3), pp. 804-810.
[cited by applicant]
Hatzimichael et al. (2010) “Hematopoietic stem cell transplantation”, Stem Cells and Cloning: Advances and Applications, 3:105-117.
[cited by applicant]
Hessell et al. (Sep. 6, 2007) “Fc Receptor but Not Complement Binding is Important in Antibody Protection Against HIV”, Nature, 449(7158):101-104.
[cited by applicant]
Hezareh et al. (Dec. 2001) “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1”, Journal of Virology, 75(24):12161-12168.
[cited by applicant]
Hughes et al. (Apr. 2005) “Transfer of a TCR Gene Derived from a Patient with a marked Antitumor Response Conveys Highly Active T-Cell Effector Functions”, Human Gene Therapy, 16(4):457-472.
[cited by applicant]
Jakobisiak et al., Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine & Growth Factor Reviews. 2011; 22:99-108.
[cited by applicant]
Kaspar et al. (May 15, 2007) “The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis Cancer Research”, American Association for Cancer Resea…
[cited by applicant]
Khantasup et al. (Dec. 1, 2015) “Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application”, Monoclonal Antibodies in mmunodiagnosis and Immunotherapy, 34(6):404…
[cited by applicant]
Kim et al. (2012) “Humanization by CDR Grafting and Specificity-Determining Residue Grafting”, Methods in molecular biology, 907:237-245.
[cited by applicant]
Kim, Yon Su et al., “Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fcγ 2a Protein Blocks Delayed-Type Hypersensitivity,” The Journal of Immunology, vol. 160(1998):5742-5748.
[cited by applicant]
Kimmel (1987) “Identification and Characterization of Specific Clones: Strategy for Confirming the Validity of Presumptive Clones”, Methods in Enzymology, 152:507-511.
[cited by applicant]
Klebanoff et al. (Feb. 17, 2004) “IL-15 Enhances the in Vivo Antitumor Activity of Tumor-Reactive CD8+ T Cells”, Proceedings of the National Academy of Sciences of the United States of America, 101(7):1969-1974.
[cited by applicant]
Lawrencia et al. (May 2001) “Transfection of Urothelial Cells using Methyl-β-Cyclodextrin Solubilized Cholesterol and Dotap”, Gene Therapy, 8(10):760-768.
[cited by applicant]
Lazar et al. (Mar. 1988) “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”, Molecular and Cellular Biology, 8(3):1247-1252.
[cited by applicant]
Matsumoto et al., Intravesical Interleukin-15 Gene Therapy in an Orthotopic Bladder Cancer Model. Human Gene Therapy. Nov. 2011; 22:1423-1432.
[cited by applicant]
McLaughlin et al. (2015) “Adoptive T -cell therapies for refractory/ relapsed leukemia and lymphoma: current strategies and recent advances”, Therapy Advance Hematology, 6(6):295-307.
[cited by applicant]
Mortier et al. (Jan. 20, 2006) “Soluble Interleukin-15 Receptor α (IL-15Rα)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rβ/γ”, The Journal of Biological Chemistry, 281(3):1612-1619.
[cited by applicant]
Moskaug et al. (Sep. 15, 1989) “Translocation of Diphtheria Toxin A-Fragment to the Cytosol. Role of The Site of Interfragment Cleavage”, Journal of Biological Chemistry, 264(26):15709-15713.
[cited by applicant]
Mosquera et al. (Apr. 1, 2005) “In Vitro And In Vivo Characterization Of A Novel Antibody-Like Single-Chain TCR Human IgG1 Fusion Protein”, Journal of Immunology, 174(7):4381-4388.
[cited by applicant]
Ng et al. (2005) “Liposomal Polyene Antibiotics”, Methods in Enzymology, 391 :304-313.
[cited by applicant]
Nogawa et al. (Apr. 2005) “Intravesical Administration of Small Interfering RNA Targeting PLK-1 Successfully Prevents the Growth of Bladder Cancer”, Journal of Clinical Investigation, 115(4):978-985.
[cited by applicant]
Olsnes et al. (1982) “Chimeric Toxins”, Pharmacology and Therapeutics, 15(3):355-381.
[cited by applicant]
Orti et al. (2017) “Donor lymphocyte infusions in AML and MOS: Enhancing the grafl-versus-leuke1nia effect”, Experimental Hematology, 48:1-11.
[cited by applicant]
Ortiz-Sanchez et al. (May 2008) “Antibody-cytokine Fusion Proteins: Applications in Cancer Therapy”, Expert Opinion on Biological Therapy, 8(5):609-632.
[cited by applicant]
Otegbeye et al. (Dec. 3, 2015) “The IL-15 Super-Agonist AL T-803 Promotes Superior Activation and Cytotoxicity of Ex Vivo Expanded NK Cells Against AML”, Blood, 3090, 126(23):4 Pages.
[cited by applicant]
Ozdemir et al. “Mechanisms of Superior Anti-Tumor Cytotoxic Response of Interleukin 15-Induced Lymphokine-Activated Killer Cells,” Journal of Immunotherapy, Jan./Feb. 2005, vol. 28(1). pp. 44-52.
[cited by applicant]
Pastan et al. (1992) “Recombinant Toxins as Novel Therapeutic Agents”, Annual Review Biochemistry, 61:331-354.
[cited by applicant]
Pastan et al. (Dec. 5, 1986) “Immunotoxins”, Cell, 47:641-648.
[cited by applicant]
Penichet et al. (1997) “Antibody-IL-2 Fusion Proteins: A Novel Strategy for Immune Protection”, Human Antibodies, 8(3):106-118.
[cited by applicant]
Pettit et al. (Jan. 24, 1997) “Structure-Function Studies of Interleukin 15 Using Site- Specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling”, Journal of Biological Chemistry, 272(4):2312-2318.
[cited by applicant]
Powles et al., “MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer,” Nature, Letter, Nov. 27, 2014, vol. 515(7528), 12 pages.
[cited by applicant]
Quemener, Agnes et al., “Docking of Human Interleukin-15 to its Specific Receptor alpha Chain: Correlation Between Molecular Modeling and Mutagenesis Experimental Data,” Proteins: Structure, Function and Bioinformatics,…
[cited by applicant]
Rabinowitz et al. (Feb. 20, 1996) “Kinetic Discrimination in T-cell Activation”, Proceedings of the National Academy of Sciences of the United States of America, 93(4):1401-1405.
[cited by applicant]
Ramos et al. (Apr. 10, 2015) “Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia”, Journal of Clinical Medicine, 4:665-695.
[cited by applicant]
Rossi et al. (Oct. 29, 2009) “CD20-Targeted Tetrameric Interferon-α, A Novel and Potent Immunocytokine for the Therapy of B-Cell Lymphomas”, Blood, 114(18):3864-3871.
[cited by applicant]
Rossi et al., “Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties,” Bioconjugate Chemistry. 2013, vol. 24, pp. 63-71.
[cited by applicant]
Roychowdhury et al. (Nov. 1, 2004) “Failed 1-15 Adoptive Immunotherapy with Tumor-Specific T Cells: Reversal with Low-Dose Interleukin 15 but not Low-Dose Interleukin 2”, Cancer Research, 64(21):8062-8067.
[cited by applicant]
Rubinstein et al. (Jun. 13, 2006) “Converting IL-15 to a Superagonist by Binding to Soluble IL-15Rα”, Proceedings of the National Academy of Sciences of the United States of America, 103(24):9166-9171.
[cited by applicant]
Sauter et al. (Apr. 29, 2013) “Interleukin-15 Administration Increases Graft-Versus-Tumor Activity in Recipients of Haploidentical Hematopoietic SCT”, Bone Marrow Transplantation, 48(9):1237-1242.
[cited by applicant]
Savio, Alicia Santos, “IL-15: a relevant cytokine for lymphoid homeostasis and autoimmune diseases,” Biotecnologia Aplicada, vol. 23 (2006):87-93.
[cited by applicant]
Schmohl et al. (Jul. 2016) “Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker”, TriKE Facilitates ADCC and Sustaining of NK Cells, Molecul…
[cited by applicant]
Skolnick, Jeffrey et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends Biotechnol., vol. 18 Issue 1 (2000):34-39.
[cited by applicant]
Sprent et al. (Mar. 29, 2000) “T-cell proliferation in vivo and the role of cytokines”, Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences, 355(1395):317-322.
[cited by applicant]
Steel, Interleukin-15 and its Receptor Augment Dendritic Cell Vaccination Against the neu Oncogene Through the Induction of Antibodies Partially Independent of CD4-help. Cancer Res. Feb. 1, 2010; 70(3): 1-19.
[cited by applicant]
Stoklasek et al. (Nov. 1, 2006) “Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity in Vivo”, Journal of Immunology, 177(9):6072-6080.
[cited by applicant]
Sukumar (Nov. 4, 2015) “Modulating Immunometabolism of Tumor Specific Mouse and Human Lymphocytes to Enhance T Cell Based Therapy for Cancer”, Journal for Immuno Therapy of Cancer, 02, 2(Suppl 3): 2 pages.
[cited by applicant]
Tai et al. (Sep. 15, 2010) “The Role of HER2 in Cancer Therapy and Targeted Drug Delivery”, Journal of Controlled Release, 146(3):264-275.
[cited by applicant]
Tay et al. (Jul. 26, 2016) “TriKEs and BiKEs Join CARs on the Cancer Immunotherapy Highway”, Human Vaccines & Immunotherapeutics, 12(11):2790-2796.
[cited by applicant]
Terawaki et al. (Jul. 2007) “Specific and High-affinity Binding ofTetramerized PD-L 1 Extracellular Domain to PD-1-expressing Cells: Possible Application to Enhance T Cell Function”, International Immunology, 19(7):881-…
[cited by applicant]
Tietze et al. (Mar. 29, 2012) “Delineation of Antigen-Specific and Antigen-Nonspecific CD8+ Memory T-Cell Responses after Cytokine-Based Cancer Immunotherapy”, Blood, 119(13):3073-3083.
[cited by applicant]
Tokuriki et al., “Stability effects of mutations and protein evolvabilily,” Current Opinion in Structural Biology, 2009, vol. 19, pp. 596-604.
[cited by applicant]
Tomalia (1993) “StarburstCascade Dendrimers: Fundamental Building Blocks for a New Nanoscopic Chemistry Set”, Aldrichimica Acta, 26(4):89-101.
[cited by applicant]
Tonegawa (Apr. 14, 1983) “Somatic Generation of Immune Diversity”, Bioscience Reports, 8(1):3-26.
[cited by applicant]
Tough et al. (May 15, 2001) “An IFN-γ-Dependent Pathway Controls Stimulation of Memory Phenotype CD8+ T Cell Turnover in Vivo by IL-12, IL-18, and IFN-γ”, Journal of Immunology, 166(10):6007-6011.
[cited by applicant]
Trevisani et al. (Jun. 2002) “Ethanol Elicits and Potentiates Nociceptor Responses via the Vanilloid Receptor-1”, Nature Neuroscience, 5(6):546-551.
[cited by applicant]
Trevisani et al. (Jun. 2004) “Ethanol Causes Inflammation in the Airways by a Neurogenic and TRPV1-Dependent Mechanism”, Journal of Pharmacology and Experimental Therapeutics, 309(3): 1167-1173.
[cited by applicant]
Tyagi et al. (Jan. 2004) “Urodynamic and Immunohistochemical Evaluation of Intravesical Capsaicin Delivery using Thermosensitive Hydrogel and Liposomes”, The Journal of Urology, 171 (1):483-489.
[cited by applicant]
Urlaub et al. (Jul. 1980) “Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity”, PNAS, 77(7):4216-4220.
[cited by applicant]
Valencia et al. (Mar. 15, 2013) “In Vitro Selection of Proteins with Desired Characteristics Using mRNA-display”, Methods, 60(1):32 pages.
[cited by applicant]
Valitutti (May 11, 1995) “Serial Triggering of Many T-Cell Receptors by a Few Peptide-MHC Complexes”, Nature, 375(6527):148-151.
[cited by applicant]
Van Den Bergh et al. (2015) “Interleukin-15: New Kid on the Block for Antitumor Combination Therapy” Cytokine and Growth Factor Reviews, 26:15-24.
[cited by applicant]
Verbist et al., Functions of IL-15 in Anti-Viral Immunity: Multiplicity and Variety. Cytokine. Sep. 2012; 59(3):467-478.
[cited by applicant]
Villinger et al. (Sep. 3, 2004) “IL-15 is Superior to IL-2 in the Generation of Long-Lived Antigen Specific Memory CD4 And CD8 T Cells in Rhesus Macaques”, Vaccine, 22(25-26):3510-3521.
[cited by applicant]
Vincent et al. (Aug. 1, 2013) “Tumor Targeting of the IL-15 Superagonist RU by an anti-GD2 Antibody Strongly Enhances Its Antitumor Potency”, International Journal of Cancer, 133(3):757-765.
[cited by applicant]
Vincent et al. (Nov. 2013) “Antitumor Activity of an Immunocytokine Composed of an Anti-GD2 Antibody and the IL-15 Superagonist RLI”, Oncolmmunology, e26441, 2(11):3 pages.
[cited by applicant]
Vincent et al. (Oct. 2011) “Development of Two IL 15 Immunocytokines Targeting Either GD2- or CD20-tumoral Bearing Cells”, Cytokine, 56(1):1 page.
[cited by applicant]
Wahl et al. (1987) “Molecular Hybridization of Immobilized Nucleic Acids: Theoretical Concepts and Practical Considerations”, Methods in Enzymology, 152:399-407.
[cited by applicant]
Waldmann et al., IL-15 Receptor, 2000, pp. 1521-1528.
[cited by applicant]
Waldmann, Thomas A., “The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design,” Nature Reviews Immunology, vol. 6 Issue 8 (2006):595-601.
[cited by applicant]
Ward et al. (Nov. 2009) “
[cited by applicant]
Weers et al., “Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors,” The Journal of Immunology, 2011, vol. 186(3), pp. 1840-1848.
[cited by applicant]
Wei et al. (2001) “The Sushi Domain of Soluble IL-15 Receptor a Is Essential for Binding IL-15 and Inhibiting Inflammatory and Allogenic Responses In Vitro and In Vivo”, The Journal of Immunology, 167:277-282.
[cited by applicant]
Weidanz et al. (Dec. 1, 1996) “Display of Functional αβ Single-Chain T-Cell Receptor Molecules on the Surface of Bacteriophage”, Journal of Immunological Methods, 221 (1-2):59-76.
[cited by applicant]
Wells (Sep. 18, 1990) “Additivity of Mutational Effects in Proteins”, Biochemistry, 29(37):8509-8517.
[cited by applicant]
Wen et al. (2008) “Targeting Activity of a TCR/IL-2 Fusion Protein Against Established Tumors” Cancer Immunology Immunother, 57(12):1781-1794.
[cited by applicant]
Whitlow et al. (Apr. 1991) “Single-Chain Fv Proteins and their Fusion Proteins”, Methods: A Companion to Methods in Enzymology, 2(2):97-105.
[cited by applicant]
Wolchok et al., “Nivolumab plus Ipilimumab in Advanced Melanoma,” New England Journal of Medicine, Jun. 2, 2013, vol. 369(2), pp. 122-133.
[cited by applicant]
Wong et al. (2011) “Interleukin-15: Interleukin-15 Receptor α Scaffold for Creation of Multivalent Targeted Immune Molecules”, Protein Engineering, Design & Selection, 24(4):373-383.
[cited by applicant]
Wong et al. (Nov. 1, 2013) “The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity”, Oncoimmunology, 2(11): e26442…
[cited by applicant]
Wu (Oct. 28, 2013) “IL-15 Agonists: The Cancer Cure Cytokine”, Journal of Molecular and Genetic Medicine, 7(4):6 pages.
[cited by applicant]
Wu, IL-15 Agonists: The Cancer Cure Cytokine. J Mol Genet Med. Feb. 28, 2014; 7(85):1-6.
[cited by applicant]
Xiao et al. “Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-a and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model,” Clinical Medicine Insights: Oncology, 20…
[cited by applicant]
Xiong et al., “Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 + anti-CD3 bispecific diabody,” Cancer Letters, 2002, vol. 177, pp. 29-39.
[cited by applicant]
Xu et al. (May 15, 2013) “Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interieukin-15 Receptor aSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma”, Therapeutics, Targets and…
[cited by applicant]
Xuan et al. (Apr. 8, 2010) “Targeted Delivery of Interferon-Alpha via Fusion to Anti-CD20 Results in Potent Antitumor Activity against B-Cell Lymphoma”, Blood, 115(14):2864-2871.
[cited by applicant]
Yu et al. (Apr. 17, 2012) “Simultaneous Inhibition ofTwo Regulatory T-Cell Subsets Enhanced Interleukin-15 Efficacy in a Prostate Tumor Model”, Proceedings of the National Academy of Sciences of the United States of Ame…
[cited by applicant]
Yu et al. (Dec. 15, 2010), e-Published (Oct. 5, 2010) “Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metasttc Colon Crcinoma Mo…
[cited by applicant]
Yu et al., “Antitumor Effects of Recombinant BCG and Interleukin-12 DNA Vaccines on Xenografted Murine Bladder Cancer,” Urology, Mar. 2004, vol. 63(3), pp. 596-601.
[cited by applicant]
Zah et al. (Jun. 2016) “T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells”, Cancer Immunology Research, 4(6):498-508.
[cited by applicant]
Zhang et al. (May 1998) “Potent and Selective Stimulation of Memory-Phenotype CD8+ T Cells in Vivo by IL-15”, Immunity, 8(5):591-599.
[cited by applicant]
Zhang et al. (May 5, 2009) “Interleukin-15 Combined with an Anti-CD40 Antibody Provides Enhanced Therapeutic Efficacy for Murine Models of Colon Cancer”, Proceedings of the National Academy of Sciences of the United Sta…
[cited by applicant]
Zhu et al. (Mar. 1, 2006) “Visualization of p53264-272/HLA-A*0201 Complexes Naturally Presented on Tumor Cell Surface by a Multimeric Soluble Single-Chain T Cell Receptor”, Journal of Immunology, 176(5):3223-3232.
[cited by applicant]
Zhu et al. (Sep. 15, 2009) “Novel Human Interleukin-15 Agonists”, Journal of Immunology, 183(6):3598-3607.
[cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/US2008/005918, mailed on Sep. 4, 2008, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2008/005918, dated Nov. 17, 2009 5 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/US2011/052545, mailed on May 2, 2012, 16 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2011/052545, mailed on Apr. 4, 2013, 12 pages.
[cited by applicant]
Extended European Search Report for European Patent Application No. 21152304.8, dated Jun. 14, 2021 9 pages.
[cited by applicant]
Official Action for European Patent Application No. 21152304.8, dated Jul. 26, 2021 2 pages.
[cited by applicant]
Official Action for European Patent Application No. 21152304.8, dated Apr. 14, 2022, 4 pages.
[cited by applicant]
Notice of Allowance for European Patent Application No. 21152304.8, dated Oct. 25, 2023, 7 pages.
[cited by applicant]
Official Action (with English translation) for Chinese Patent Application No. 201711167564.4, dated Sep. 10, 2021 4 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent International Application No. PCT/US2015/038587, Mailed on Oct. 15, 2015, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT International Application No. PCT/US2015/038587, mailed on Jan. 12, 2017, 8 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent International Application No. PCT/US2016/053230, mailed on Dec. 30, 2016, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT International Application No. PCT/US2016/053230, mailed on Apr. 5, 2018, 8 pages.
[cited by applicant]
Official Action for U.S. Appl. No. 16/442,265, dated Jan. 14, 2021 5 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/442,265, dated Apr. 29, 2021 6 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/749,967, dated Apr. 29, 2021 8 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/749,955, dated Mar. 5, 2021 9 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/385,714, dated Jul. 26, 2023, 9 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/385,714, dated Oct. 27, 2023, 8 pages.
[cited by applicant]
Davies, “New modalities of cancer treatment for NSCLC: focus on immunotherapy,” Cancer Management Res, Feb. 3, 2014, vol. 6, pp. 63-74.
[cited by applicant]
Schietinger et al., “Tolerance and exhaustion: defining mechanisms of T Cell dysfunction,” Trends in Immunology, Feb. 2014, vol. 35(2), pp. 51-60.
[cited by applicant]
Umemura et al., “Overexpression of IL-15 In Vivio Enhances Protection Against
[cited by applicant]